Biodexa Pharmaceuticals Plc
corporate_fare Company Profile
Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) is a publicly traded company in the Life Sciences sector. Wiseek monitors BDRX SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.
Recent high-impact activity:
- Biodexa Registers Resale of 2.55M ADSs from July $3.54M Offering, Enabling Potential Dilution
- Biodexa Sets July 29 Vote on 1-for-10,000 Reverse Split and £25M Share Authorization
- Biodexa Finalizes $3.54M Offering at Discount, Adding Significant Warrants
- Biodexa Finalizes $3.54M Offering, Highly Dilutive at 269% of Market Cap
- Biodexa Pharmaceuticals Finalizes Highly Dilutive $3.54M Offering at Discounted Price
Financial Snapshot
Dilution Risk
High riskFiling-implied dilution signals for BDRX, detected from its recent SEC filings · based on capital-structure filings through 2026-07-15.
Multi-Part Offering Finalized · Discounted Pricing
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
BDRX files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.